[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics (ALDX), reported the sale of 22,073 shares of common stock on 08/11/2025. The disposals were executed to cover tax withholding obligations upon settlement of time-based restricted stock units. The sales produced a weighted average price of $5.1517, with individual trade prices in the range of $5.06 to $5.29. After the reported transactions the reporting person beneficially owned 221,799 shares, which includes 7,101 shares acquired under the company’s Employee Stock Purchase Plan. No derivative securities were reported.

Positive

• Sale was for tax withholding upon RSU settlement, explicitly stated in the filing
• Reporting person retains 221,799 shares of common stock, including 7,101 ESPP shares, after the transaction
• Weighted average sale price disclosed ($5.1517) with the reported price range ($5.06 to $5.29), improving transparency

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine tax-related sale of RSU shares; insider retains substantial direct holdings with no derivatives reported.

The filing shows a standard compensation-related sale rather than an open-market diversification event. The disposition of 22,073 shares was explicitly for tax withholding upon RSU settlement, and the reporting person continues to hold 221,799 shares directly, including 7,101 ESPP shares. The absence of derivative transactions reduces complexity for governance review. This is a customary disclosure under Section 16 and does not itself indicate a change in corporate control or governance policy.

Securities Analyst

TL;DR: Transaction is operationally routine and neutral; sale details provide transparent pricing and share counts for investor records.

The report records a sale conducted at a weighted average price of $5.1517 with trades between $5.06 and $5.29. The reason provided—covering tax withholding for time-based RSUs—is explicitly stated, which clarifies intent and reduces interpretive risk. Post-transaction direct beneficial ownership of 221,799 shares is disclosed, which is useful for modeling potential insider alignment but requires context of total outstanding shares to assess materiality.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Machatha Stephen

(Last) (First) (Middle)

C/O ALDEYRA THERAPEUTICS, INC.

131 HARTWELL AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aldeyra Therapeutics, Inc. [ ALDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2025		S(1)		22,073	D	$5.1517(2)	221,799(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.

	/s/ Stephen Machatha	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ALDX insider Stephen Machatha do according to the Form 4?

The filing reports that Stephen Machatha sold 22,073 shares of Aldeyra Therapeutics common stock on 08/11/2025.

Why were the shares sold by the ALDX reporting person?

The shares were sold to cover tax withholding obligations upon settlement of certain time-based restricted stock unit awards, as stated in the filing.

At what price were the ALDX shares sold?

The filing reports a weighted average sales price of $5.1517, with individual sales priced between $5.06 and $5.29.

How many ALDX shares does the reporting person own after the transaction?

After the reported transactions the reporting person beneficially owned 221,799 shares, which includes 7,101 shares acquired under the Employee Stock Purchase Plan.

Were any derivative securities reported in this Form 4 for ALDX?

No. Table II shows no derivative securities acquired, disposed of, or beneficially owned in this filing.

Does the filing state whether the reporting person filed jointly or individually?

The filing indicates it was filed by one reporting person (individual filing).